Industry News

The latest news from the clinical trials industry.

News Powered By:

- a collaborative partner.


 


3SBio acquires Sirton Pharmaceuticals


CenterWatch News Online Headlines : January 26, 2015 8:25 am : Centerwatch

3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.



Actavis to acquire Auden Mckenzie for $461.8 million


CenterWatch News Online Headlines : January 26, 2015 8:24 am : Centerwatch

Actavis, a global specialty pharmaceutical company, will acquire Auden Mckenzie, a company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the U.K., for approximately $461.8 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products.



Covance launches new solution to bridge preclinical to clinical development


CenterWatch News Online Headlines : January 26, 2015 6:48 am : Centerwatch

Princeton, N.J.-based CRO Covance has introduced Covance Early Phase Development Solutions, a multi-disciplined approach to early drug development, partnership and continuity to generate greater value in asset development and achieve accelerated delivery timelines.



Novotech expands operation in Hong Kong


CenterWatch News Online Headlines : January 26, 2015 6:46 am : Centerwatch

Sydney, Australia-based Novotech has expanded its Hong Kong operation into a permanent office with more staff to meet the increasing demand in the pharmaceutical market for clinical research.



EMA recommends suspending medicines over flawed studies


CenterWatch News Online Headlines : January 26, 2015 6:43 am : Centerwatch

A number of medicines for which authorization in the European Union (E.U.) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, according to the EMA. The recommendation is based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of marketing authorization holders.


« Page 1, 2, 3535, »